Head and Neck Cancer (HNC) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025
Head and Neck
Cancer (HNC) Emerging Therapy and TPP Insights
Thelansis’s “Head
and Neck Cancer (HNC) Emerging Therapy, with Unmet Needs and TPP Insights
Report – 2025″ provides a comprehensive analysis of the emerging
competitive landscape, unmet needs, target product profiles (TPPs), trial
designs, and KOL insights on key emerging therapies and key drug development
opportunities in the indication.
Head and Neck
Cancer (HNC) Overview
Head and neck cancer affects nearly
65,000 individuals annually in the United States. Excluding skin and thyroid
cancers, over 90% of head and neck malignancies are squamous cell carcinomas
(SCCs); the remainder predominantly consists of adenocarcinomas, sarcomas, and
lymphomas. A significant majority, exceeding 85%, of patients with head and
neck cancer have a history of alcohol consumption, tobacco use, or both.
Chronic heavy use of tobacco and alcohol increases the risk of developing
squamous cell carcinoma by approximately 40-fold. Other potential risk factors
include the use of smokeless tobacco, exposure to sunlight, prior radiation
therapy of the head and neck, certain viral infections, poorly fitting dental
appliances, chronic candidiasis, and inadequate oral hygiene. In India, the
high prevalence of oral cancer is attributed to the chewing of betel quid
(paan). For squamous cell carcinoma of the lower lip, prolonged sunlight
exposure and tobacco use are the primary etiological factors.
Geography
coverage:
G8 (United
States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights
driven by surveys* with physician / key opinion leaders:
- Survey findings are corroborated and
enriched by insights from interviews with leading KOLs
*Survey is
customized based on client requirements
Deliverables
format:
- PowerPoint presentation
- MS Excel
Key business
questions answered:
- Detailed emerging competitive
landscape
- Pipeline
analysis
- Target patients
for emerging therapies
- Key companies
- Key mechanism of
actions
- Launch date
estimates, etc.
- Clinical trial landscape analysis
- Target patient
segments
- Trial endpoints
- Trial design
- Recruitment
criteria, etc.
- Unmet Needs and Opportunities
- Performance of
key current therapies
- Top areas of
unmet needs
- Opportunity
sizing for key unmet needs
- Target Product Profiles
- Attributes and
levels
- Physician
likelihood of prescribing
- Expected patient
shares
- KOL insights on key emerging
therapies
- Level of
awareness
- Expected use /
line of therapy
- Extent to fulfil
key unmet needs
- KOL quotes
Read more: Head and Neck Cancer (HNC) – Emerging Therapy, with
Unmet Needs and TPP Insights Report – 2025
Comments
Post a Comment